Medical Articles 10/23

Posted by rob on October 23, 2008 under Uncategorized | Be the First to Comment

Variation in supportive care practices in hematopoietic cell transplantation.

CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri.

Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response.

Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.

Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.

Chronic myeloid leukaemia: the evolution of gene-targeted therapy.

[Imatinib therapy in chronic myeloid leukemia]

Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis.

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.

Medical Articles 10/19

Posted by rob on October 19, 2008 under Uncategorized | Be the First to Comment

Fms-like Tyrosine Kinase (FLT) 3 and FLT3 Internal Tandem Duplication in Different Types of Adult Leukemia: Analysis of 147 Patients.

Myelodysplastic syndromes: diagnosis and staging.

Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.

Buffalo Tools generators at http://generatorzoo.com

Medical Articles 10/10

Posted by rob on October 10, 2008 under Uncategorized | Be the First to Comment

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.

Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.

Deep discount prices on home standby generators at http://generatorzoo.com

Medical Articles 10/8

Posted by rob on October 8, 2008 under Uncategorized | Be the First to Comment

STI571-Induced Cell Edge Translocation of Kinase-Active and Kinase-Defective Abl: Requirements of Myristoylation and SH3 Domain.

2,2′-Bipyridinebutyldithiocarbamatoplatinum(II) and palladium(II) complexes: Synthesis, characterization, cytotoxicity, and rich DNA-binding studies.

Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.

Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease.

Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH.

Medical Articles 10/2

Posted by rob on October 2, 2008 under Uncategorized | Be the First to Comment

In vitro and in vivo Study of Cell Growth Inhibition of Simvastatin on Chronic Myelogenous Leukemia Cells.

Familial Mediterranean Fever Gene as a Possible Modifier of Sweet Syndrome with Chronic Myelogenous Leukemia.

Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors.

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

Severe renal complications in chronic myelomonocytic leukemia.

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.